Skip to main content
. 2022 Feb 28;40(15):2331–2341. doi: 10.1016/j.vaccine.2022.02.054

Fig. 4.

Fig. 4

(A.) A linear pool cumulative predictive density of trained forecasters and experts over dates for when an approved SARS-CoV-2 vaccine in the US or European Union will be administered to more than 100,000 people. (B.) Linear pool cumulative predictive densities of the number of weeks after approval needed to manufacture 100,000,000 doses of a vaccine using a DNA/RNA platform (purple dashed line) and a vaccine using a viral vector platform (red solid line).